Micafungina Hikma (Micafungin Sodium)

Micafungin sodium blocks the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for building β‑(1,3)‑D‑glucan, a key component of the fungal cell wall. Inhibiting this pathway weakens the cell wall, causing osmotic instability and ultimately leading to fungal cell death while sparing human cells that lack this polymer.

The dose of Micafungina Hikma is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and the severity of the infection. Dosage regimens are individualized and should follow the latest clinical guidelines and the product’s prescribing information.

Safety data for micafungin sodium in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainty with patients and consider alternative therapies when appropriate.

To order Micafungina Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Micafungina Hikma belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis or polyenes that bind membrane sterols. Echinocandins generally have a favorable safety profile, limited drug‑drug interactions, and are effective against many Candida species, including some azole‑resistant strains.

Micafungina Hikma should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures product stability and potency until the time of administration.

Micafungina Hikma is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein. The infusion rate and duration are set by the prescribing clinician, typically over a period of 30‑60 minutes, and the medication is given under aseptic conditions in a clinical setting.

Serious adverse events reported with micafungin include hepatotoxicity (significant liver enzyme elevation or jaundice), severe hypersensitivity reactions such as anaphylaxis, and hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored closely for signs of liver dysfunction, allergic reactions, and blood count changes during therapy.

Micafungina Hikma is contraindicated in patients with known hypersensitivity to micafungin sodium or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled renal impairment, or those receiving drugs that may cause additive toxicity without appropriate monitoring.